GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Sulbactam/durlobactam (XACDURO)

Local official-label summaryBase record retrieved 2026-09-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

Xacduro

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Exact-130 threshold differs between printed sources

At CrCl exactly 130 mL/min, the printed UCSF band uses a six-hour interval; the official label places 130 in the four-hour band.

Before applying: Do not average these intervals. Confirm current labeling and the local protocol before clinical use.

Also check: Exact-130 threshold differs between printed sources

Official source

XACDURO - sulbactam/durlobactam injection

Product / population
Adults at least 18 years old; HABP/VABP caused by susceptible Acinetobacter baumannii-calcoaceticus complex.
Renal measure
CrCl by Cockcroft-Gault, mL/min.

Renal dosing, restrictions and evidence limits

Each dose contains sulbactam 1 g plus durlobactam 1 g. Infuse every dose intravenously over 3 hours.

CrClDose interval
At least 130Every 4 hours
45-129Every 6 hours
30-44Every 8 hours
15-29Every 12 hours
Below 15, new treatmentEvery 12 hours for the first three doses at 0, 12 and 24 hours; then every 24 hours
Below 15, decline during treatmentEvery 24 hours

For intermittent HD, initiate dosing immediately after HD; administer doses after the session. Monitor fluctuating renal function and revise the interval accordingly. This extract does not provide a CRRT regimen.

Source revision: Prescribing information revised May 2023; DailyMed page updated November 26, 2025. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72

Scope: Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

XACDURO - sulbactam/durlobactam injection

Adults at least 18 years old; HABP/VABP caused by susceptible Acinetobacter baumannii-calcoaceticus complex.

Renal method: CrCl by Cockcroft-Gault, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - XACDURO

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; sulbactam/durlobactam fixed IV combination. Not sulbactam alone or ampicillin/sulbactam.

Renal method: Cockcroft-Gault CrCl, mL/min; intermittent HD is separate from CRRT.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

UCSF - sulbactam/durlobactam renal and HD regimens

Adult IV sulbactam/durlobactam; restricted to infectious-disease/antimicrobial-stewardship approval for carbapenem-resistant Acinetobacter infections.

Renal method: CrCl, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source ambiguity

Exact-130 threshold differs between printed sources

At CrCl exactly 130 mL/min, the printed UCSF band uses a six-hour interval; the official label places 130 in the four-hour band.

How to use this: Do not average these intervals. Confirm current labeling and the local protocol before clinical use.

XACDURO - sulbactam/durlobactam injectionUCSF - sulbactam/durlobactam renal and HD regimens

Source difference identified; final patient-specific adjudication required.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeXACDURO - sulbactam/durlobactam injectionGlobalRPh RX List - XACDUROUCSF - sulbactam/durlobactam renal and HD regimens
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://idmp.ucsf.edu/content/sulbactam-durlobactam

Product and population scope

Adult IV fixed combination; specialist-restricted infection protocol.

RDM33-SCOPE-sulbactam-durlobactam-C1 · Source section: Exact product identity and selected populationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

XACDURO - sulbactam/durlobactam injection

Open original reference

Open / share this exact local source

DailyMed / NLM; manufacturer prescribing information · Adults at least 18 years old; HABP/VABP caused by susceptible Acinetobacter baumannii-calcoaceticus complex.

Renal method: CrCl by Cockcroft-Gault, mL/min.
Source date: Prescribing information revised May 2023; DailyMed page updated November 26, 2025.
Retrieved: 2026-09-07

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Each dose contains sulbactam 1 g plus durlobactam 1 g. Infuse every dose intravenously over 3 hours.

CrClDose interval
At least 130Every 4 hours
45-129Every 6 hours
30-44Every 8 hours
15-29Every 12 hours
Below 15, new treatmentEvery 12 hours for the first three doses at 0, 12 and 24 hours; then every 24 hours
Below 15, decline during treatmentEvery 24 hours

For intermittent HD, initiate dosing immediately after HD; administer doses after the session. Monitor fluctuating renal function and revise the interval accordingly. This extract does not provide a CRRT regimen.

RDM33-official-sulbactam-durlobactam-C1 · Source locator: Sections 1.1, 2.1-2.3 and Table 1.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72
Retrieved
2026-09-07
Exact label title
XACDURO - sulbactam/durlobactam injection
DailyMed Set ID
c0167aec-a89d-4e96-afe5-2ccf3e89fe72
Label revision
Prescribing information revised May 2023; DailyMed page updated November 26, 2025.
Renal-function method
CrCl by Cockcroft-Gault, mL/min.
Source date/version
Prescribing information revised May 2023; DailyMed page updated November 26, 2025.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
3294ba5f3a667b2b2ad4ffee2e4eecdea9f6e5e00dc0d240aaf2b6383dcffad6
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - XACDURO

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults; sulbactam/durlobactam fixed IV combination. Not sulbactam alone or ampicillin/sulbactam.

Renal method: Cockcroft-Gault CrCl, mL/min; intermittent HD is separate from CRRT.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Adult IV HABP/VABP due to susceptible Acinetobacter baumannii-calcoaceticus complex: each dose contains sulbactam 1 g plus durlobactam 1 g, infused over 3 hours. Cockcroft-Gault CrCl >=130 mL/min: every 4 hours; 45-129: every 6 hours; 30-44: every 8 hours; 15-29: every 12 hours. Below 15 when initiating treatment: every 12 hours for the first three doses (0, 12, 24 hours), then every 24 hours. If already receiving treatment and CrCl falls below 15, use every 24 hours. Give dialysis-day doses after intermittent hemodialysis. Reassess changing renal function. This source places exactly 130 in the four-hour band. It does not supply a CRRT regimen.

RDM35-rxlist-sulbactam-durlobactam-25da6bf9ed-C1 · Source locator: Dosage: renal-function table and its footnotes.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xacduro-drug/
Retrieved
2026-09-07
Renal-function method
Cockcroft-Gault CrCl, mL/min; intermittent HD is separate from CRRT.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
c56ea7c9746286768ad0a9dc77921b0f2663d15552b301ff942e00b0bc3edc5a
Separate professional-source layer

University and professional protocols

Professional

UCSF - sulbactam/durlobactam renal and HD regimens

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adult IV sulbactam/durlobactam; restricted to infectious-disease/antimicrobial-stewardship approval for carbapenem-resistant Acinetobacter infections.

Renal method: CrCl, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Each 2 g dose is sulbactam 1 g plus durlobactam 1 g.

CrClCombined IV dose
Above 1302 g every 4 hours
45-1302 g every 6 hours
30-442 g every 8 hours
15-292 g every 12 hours
Below 152 g every 24 hours

For a new start below 15, give 2 g every 12 hours for three doses before the once-daily regimen. Intermittent HD: 2 g every 12 hours for three doses, then 2 g every 24 hours; doses are given after HD. Continuous-hemodialysis data are not provided. Infusion preparation/duration and the rest of the combination-treatment protocol require the complete prescribing and institutional guidance.

RDM33-professional-sulbactam-durlobactam-C1 · Source locator: Adult non-dialysis table, footnote and intermittent-HD table.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/sulbactam-durlobactam
Retrieved
2026-09-07
Renal-function method
CrCl, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
7766e16edbe9a81a7cbb3bd0b359443ed7a75a03a2428214bf70063825423086

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://idmp.ucsf.edu/content/sulbactam-durlobactam
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
professional summary
Local text SHA-256
05d9ff01c03b855e106e8355f27ac4f6d0bc2f4aa430604bbb45b7324eedd02f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report